A Dose-Expansion Trial of Intravenous HNF4α srRNA for Unresectable or Metastatic Colorectal Cancer

This study is a single-arm, open-label, exploratory clinical trial. Building on the previous dose-escalation trial, this dose-expansion trial aims to evaluate the safety and tolerability of intravenous monotherapy with CD-GA-102 or its combination with immunotherapy and other systemic treatments in patients with unresectable locally advanced or metastatic colorectal cancer, and to preliminarily explore its efficacy in treating colorectal cancer.

Trial Details

NCT ID

NCT07050394

Phase

EARLY_PHASE1

Sponsor

Shanghai Changzheng Hospital

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

CD-GA-102

Locations (sample)

Shanghai, None Selected, China|31.22222,121.45806

Key Eligibility Criteria

Age ≥ 18 years, regardless of gender.
Patients with colorectal cancer confirmed by histology or cytology.
Patients with unresectable locally advanced or metastatic colorectal cancer.
Patients who are not suitable for or intolerant of standard systemic therapy; or patients who have progressed after receiving standard systemic the…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →